RE:RE:RE:RE:A little more information wouldn't be bad!Last time I checked one of Sanofi main focuses for R&D was hemophilia in fact they have multiple phase 3 trials going. Another one was Parkinson's. Maybe there is a reason we haven't heard anything on hemophilia? " With Ablynx and Bioverativ joining the Sanofi family, the company is now spearheading an industry-leading franchise to treat rare blood disorders. Sanofi continues to build on its legacy of innovation, from the development of the first extended half-life clotting factors for treating hemophilia A and B, using a range of technologies including further engineering clotting factor fusion proteins, small interfering RNA and gene therapy. It is developing novel therapies using insights into the complement mediated pathophysiology of other rare blood disorders, such as cold agglutinin disease, a chronic autoimmune hemolytic condition for which there are no approved therapies. Sanofi is also working to address the significant unmet medical need in sickle cell disease and other hemoglobinopathies with both small molecule and ex vivo gene editing approaches."